ABIOMED Inc
Change company Symbol lookup
Select an option...
ABMD ABIOMED Inc
GSQD G Squared Ascend I Inc
GL Globe Life Inc
MDIA Mediaco Holding Inc
SWVLW Swvl Holdings Equity Warrant Exp 31st Mar 2027 *W EXP 03/31/2027
SCBCX Franklin Multi-Asset Conservative Growth Fund C
BUI BlackRock Utilities, Infrastructure & Power Opportunities Trust
FDEU First Trust Dynamic Europe Equity Income
DOCU DocuSign Inc
DHCAU DHC Acquisition Corp
Go

Health Care : Health Care Equipment & Supplies | Mid Cap Growth
Company profile

ABIOMED, Inc. is a medical technology provider, which provides circulatory support and oxygenation. The Company develops, manufactures and markets its products, which are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. Its products are used in the cardiac catheterization lab or cath lab, by interventional cardiologists and in the heart surgery suite by cardiac surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty, or heart surgery procedures. The Company's Impella device portfolio includes the Impella 2.5, Impella CP, Impella 5.0, Impella LD, Impella 5.5 and Impella RP devices. Its product pipeline includes Impella ECP, Impella XR Sheath, Impella BTR and precardiac. The Impella ECP device is designed for blood flow of greater than three and a half liters per minute. The Impella BTR device is designed to be a heart pump with integrated motors and sensors.

Closing Price
$254.56
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
345,887
0

Display:

Providers:

UpdateCancel
6 providers
June 14, 2022
Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps

Abiomed, Inc. (NASDAQ: ABMD) today announced that it will host an investor call on the heart failure opportunity with the Impella 5.5 and future Impella BTR heart pumps on June 24, 2022 from 2:30 p.m. - 3:30 p.m. ET. The event will include...(BusinessWire)

May 31, 2022
Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference

Abiomed, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present (live) at the William Blair 42nd Annual Growth...(BusinessWire)

May 18, 2022
SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes

Abiomed (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, will feature the most recent Impella research and technological advances aimed at improving outcomes for acute myocardial infarction cardiogenic shock...(BusinessWire)

April 28, 2022
Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year

ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced financial results for the quarter and fiscal year ended March 31, 2022. Financial summary and operational highlights: (BusinessWire)

April 26, 2022
World's First Patient Implanted with Impella BTR Minimally Invasive Heart Pump

Abiomed (Nasdaq: ABMD) announces the first patient in the world has been successfully implanted with Impella Bridge-to-Recovery (BTR) as part of the heart pump's U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS). The first...(BusinessWire)

April 08, 2022
Abiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call Notification

Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, April 28, 2022, the Company will release financial results for the fourth quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, April 28...(BusinessWire)

April 06, 2022
First Patient in Japan Treated with Impella 5.5 with SmartAssist

The versatility and innovation of Abiomed's (NASDAQ: ABMD) Impella 5.5 with SmartAssist, a minimally-invasive forward flow heart pump, is leading to continued adoption of the game-changing technology by surgeons around the world. Today, Abiomed...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.